Comparison of Pain Relief After Non Stimulating Interscalene Catheter Placement vs Stimulating Catheter Placement in Total Shoulder Arthroplasty.

NCT ID: NCT01122732

Last Updated: 2016-11-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2010-08-31

Study Completion Date

2015-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

1. Interscalene continuous catheter is a very effective way of controlling pain in total shoulder arthroplasty. To ensure proper placement, nerve stimulating catheter is quite often used.
2. Ultrasound can help proper placement of catheter without relying on nerve stimulation.
3. The plan of the study is to compare two techniques head to head to see if they are equally effective or one is better than others.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

After consent patients will be randomized to one of the two groups: Control Group or the Experimental Group. Patients will be blinded to the group assignment. As both catheters are placed using almost the same technique, the subjects will be unable to tell type of catheter they will be getting..

Every procedure will be done after starting intravenous access and placing standard anesthesia monitors (EKG, Blood Pressure Cuff and Pulse-Ox) on the patients. For comfort care sedation will be titrated using accepted American Society of Anesthesiology and American society of Regional Anesthesia Guidelines.

In the Control Group the patient will have interscalene catheter placed using nerve stimulation technique. Initially ultrasound guidance will be used to visualize brachial plexus at the cricoid level with the intent to visualize upper trunks or roots. Then following established guidelines a nerve stimulating catheter will be placed. This will be done using an ARROW NERVE KIT. The kit is FAD approved for this purpose.. Following accepted aseptic guidelines the nerves will be visualized at the base of the neck using ultrasound machine. Once proper nerve roots or trunks visualized, kit provided 17gauge insulated Touhy needle will be used to access the brachial plexus. Once twitches elicited in Deltoid, biceps or triceps muscles at 0.5 mamp, catheter will be threaded via the needle while maintaining twitch at 0.5 mamp or less. Once catheter is threaded 3 cm beyond the tip, Touhy needle will be removed. Catheter will be tested for proper placement using lidocaine and epinephrine as is recommended by Regional Anesthesia Society guidelines. Thereafter 3 mg/kg of 0.5 % bupivacaine will be injected in small blouses via the catheter.

In the Experimental Group, after placement of monitors, the nerves will be visualized using ultrasound machine. Once nerve visualized at the cricoids level, proper tip of Touhy needle will be guided using hydro-dissection technique. Once in good place, catheter will be threaded 3 cm into the space. They subjects will be dosed using 0.5% bupivacaine 3 mg/kg for the surgery via the catheter. Adequacy of catheter placement will be judged by examining the spread of local anesthetics around the plexus.

The extent of block before the surgery will be evaluated at 30 minutes post injection. Surgery will be done with sedation. Conversion of anesthetic technique to general anesthesia will be considered failure of the technique to provide adequate surgical anesthesia.

At the end of the case the patient will be taken to recovery and will be evaluated for pain. If patient is having pain of 3 or more then they will be treated as follows.

In each catheter group patient will be dosed with 10 ml 1% lidocaine. If it fails to provide any relief then the catheter will be pulled back and another 10 ml1% lidocaine will be given. If still not effective then it will be replaced. Refusal of patient to replace the catheter will result in pt dropping out of the study.

Working catheter will be left in place for at least 48 hrs. Patients will be allowed to take oral pain medicines as prescribed by their surgeons. The patient will be sent home with pain pump to continuously give them 0.125% bupivacaine at 5 ml per hr with an option to get extra dose of 5 ml every one hr if needed. The pain control will be monitored while in-house and by phone daily till catheter comes out.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pain Shoulder Arthroplasty

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

nerve block continuous catheter shoulder surgery pain control after total shoulder arthroplasty

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

US Group

Interscalene catheter will be placed with US guidance without any nerve stimulation guidance.

No interventions assigned to this group

NS Group

Catheter will be placed using nerve stimulation guidance

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 yr or older
* patient agreed to continuous regional block

Exclusion Criteria

* minor
* patient refusal
* any neuropathy
* allergies to local anesthetic,
* inability to obtain informed consent for any reason, Opioid user, chronic pain patients or unanticipated procedure other than total shoulder arthroplasty
Minimum Eligible Age

18 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University of Chicago

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

TARIQ MALIK, MD

Role: PRINCIPAL_INVESTIGATOR

University of Chicago

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Chicago Hospitals

Chicago, Illinois, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

10-242-B

Identifier Type: -

Identifier Source: org_study_id